CTOs on the Move

St. John`s Episcopal Hospital

www.ehs.org

 
Episcopal Health Services (EHS) traces its roots almost 150 years back to the Church Charity Foundation which was founded on February 6, 1851 for aged indigent persons and for the welfare of orphans, half orphans, and other destitute children.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.ehs.org
  • 327 Beach 19th Street
    Far Rockaway, NY USA 11691
  • Phone: 718.869.7000

Executives

Name Title Contact Details

Similar Companies

Eagle Pharmaceuticals

Eagle Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing injectable products, primarily in the critical care and oncology areas, using the 505(b)(2) regulatory pathway.

Healthcare Services Group

Healthcare Services Group, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Healthcare Services Group, Inc. is based in Bensalem, PA. You can find more information on Healthcare Services Group, Inc. at www.hcsgcorp.com

Texas Health Network

Texas Health Network is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Austin, TX. To find more information about Texas Health Network, please visit www.tmhp.com

OriginLab Corporation

OriginLab Corporation is a Northampton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.